西妥昔单抗联合热疗及放疗诱导人鼻咽癌细胞株CNE凋亡实验研究
|
摘要
第一部分:西妥昔单抗诱导人鼻咽癌细胞株CNE凋亡实验研究
目的:观察西妥昔单抗诱导人鼻咽癌细胞株CNE凋亡的效果,并初步探讨其可能机制。方法:MTT法测定西妥昔单抗对CNE细胞株20～30%抑制的工作浓度;以该浓度药物作用CNE细胞,透射电镜、Hochest33258荧光染色法观察其凋亡形态学变化,流式细胞术检测凋亡率;western blot检测Bax、Bcl-2蛋白的表达。结果:西妥昔单抗对CNE细胞株的工作浓度(IC20～30)为10ug/ml;CNE细胞经西妥昔单抗处理后,电镜、荧光显微镜下均可见典型的凋亡形态学及超微结构改变;流式细胞术显示24、48h凋亡率分别为14.30±0.78%、15.30±0.95%,显著高于对照组(P<0.05);western blot检测显示Bax蛋白表达上调、Bcl-2蛋白表达下调、Bax/Bcl-2比值增加。结论:西妥昔单抗对人鼻咽癌细胞株CNE有显著的凋亡诱导作用,这可能与其上调Bax/Bcl-2比值促进凋亡有关。
第二部分:西妥昔单抗联合热疗诱导人鼻咽癌细胞株CNE凋亡实验研究
目的:观察西妥昔单抗联合热疗诱导人鼻咽癌细胞株CNE凋亡的效果,并初步探讨其可能的机制。方法:试验分单靶组、单热组及热靶组,Hochest33258荧光染色法观察CNE细胞株各处理组细胞凋亡形态学变化;流式细胞术检测凋亡率;western blot检测CNE细胞株不同处理后Bax、Bcl-2、EGFR以及热疗后不同时间EGFR蛋白的表达。结果:荧光染色法观察到CNE细胞发生典型的凋亡形态学改变,以热靶组更为显著;流式凋亡检测显示热靶组凋亡率显著高于单靶组、单热组及对照组(P<0.05);western blot检测显示各处理组较之对照组都有上调Bax/Bcl-2比值、下调EGFR蛋白表达作用,以热靶组最为显著(P<0.05);热疗后随时间的延长,EGFR蛋白表达逐渐下调。结论:西妥昔单抗联合低温热疗能显著增加CNE细胞的凋亡率,这可能与EGFR的下调与受抑,进而调变Bax/Bcl-2比值进一步促进凋亡有关。
第三部分:西妥昔单抗联合放疗及热疗诱导人鼻咽癌细胞株CNE凋亡实验研究
目的:观察西妥昔单抗联合放疗及低温热疗体外诱导人鼻咽癌细胞株CNE凋亡的效果,并初步探讨其可能的机制。方法:试验分对照组、单放组、热放组、靶放组及热靶放组,Hochest 33258荧光染色法观察CNE细胞株细胞凋亡形态学变化;流式细胞术检测凋亡率; Western blot检测各组Bax、Bcl-2蛋白的表达。结果:荧光染色法观察到CNE细胞发生典型的凋亡形态学改变,以靶放热组更为显著;流式凋亡检测显示各照射剂量下靶放热组凋亡率显著高于对照组及相应单放组、热放组、靶放组(P<0.05);western blot检测显示各处理组较之对照组都有上调Bax/Bcl-2比值,以靶放热组最为显著(P<0.05)。结论:西妥昔单抗联合放疗和低温热疗显著增加CNE细胞的凋亡率,这可能与其上调Bax/Bcl-2比值进一步促进凋亡有关。
Part One: The experimental study on apoptosis of human nasopharyngeal carcinoma CNE cell line induced by cetuximab in vitro Objective: To investigate the apoptosis mechanism of CNE cell line induced by cetuximab in vitro. Methods: The working concentration of cetuximab was defined as its IC(20～30) at 48 hours action against CNE which was determined by MTT assay. Cells apoptosis was assayed by transmission electron microscopy(TEM), fluorescent Hocehst 33258 staining and flow cytometric analysis(FCM). The expression of Bcl- 2、Bax proteins were determined by Western Blot. Results: A working concentration of Cetuximab at 10μg/ml was obtained and subsequently used in the following experiments. Characteristical changes of apoptosis in CNE cells were observed and the apoptosis rate of 24, 48h was 14.30±0.78%, 15.30±0.95% respectively(P<0.05 compared with control group). In addition, Western Blot analysis indicated the level of expression of the proteins Bax significantly increased while Bcl-2 decreased by the treatment. Conclusion: Cetuximab could significantly induce the apoptosis of CNE cells, possibly through the Bax up-regulation and Bcl-2 down-regulation.
Part Two : The experimental study on apoptosis of human nasopharyngeal carcinoma CNE cell line induced by cetuximab combined with hyperthermia in vitro
Objective: To investigate the apoptosis mechanism of CNE cell line induced by cetuximab combined with hyperthermia in vitro. Methods: Apoptosis was assayed by fluorescent Hochest 33258 staining and flow cytometry(FCM) in three experimental groups: cetuximab(10ug/ml) or hyperthermia(43℃, 30min) alone, cetuximab combined with hyperthermia. The expression of Bax, Bcl-2, EGFR proteins were determined by Western Blot. Results: Characteristical changes of apoptosis in CNE cells were observed in all experimental groups, especially in cetuximab combined with hyperthermia group. FCM also showed more prominent apoptosis induced by cetuximab combined with hyperthermia group compared to cetuximab or hyperthermia alone groups. Western Blot analysis indicated that the ratio of Bax/Bcl-2 significantly increased while the expression of the protein EGFR decreased by the treatment,the level of expression of the protein EGFR decreased gradually after the treatment of hyperthermia. Conclusion: Cetuximab combined with hyperthermia synergistically increases the apoptosis in CNE cells, possibly by further down-regulating expression of EGFR to up-regulate Bax/Bcl-2 ratio.
Part Three : The experimental study on apoptosis of human nasopharyngeal carcinoma CNE cell line induced by cetuximab in conjunction with radiotherapy and hyperthermia in vitro
Objective: To investigate the apoptosis mechanism of CNE cell line induced by Cetuximab in conjunction with radiotherapy and hyperthermia in vitro. Methods:Apoptosis was assayed by fluorescent Hocehst 33258 staining and flow cytometry (FCM) in five experimental groups: control with no treatment (C), radiotherapy alone(2、4、8、12Gy)(R), Cetuximab with radiotherapy(TR), Cetuximab with hyperthermia(43℃, 30min)(TH), and Cetuximab with radiotherapy plus hyperthermia(TRH). The expression of Bcl-2, Bax proteins were determined by Western Blot. Results: Characteristical changes of apoptosis in cells treated with cetuximab were observed in all the experimental groups, especially in TRH. FCM also showed more prominent apoptosis induced by TRH group compared to the control, R, TR and RH groups. In addition, Western Blot analysis indicated that the ratio of the proteins Bax/Bcl-2 by the treatment. Conclusion: Cetuximab in conjunction with radiotherapy and hyperthermia synergistically increases the apoptosis in CNE cells, possibly through further up-regulation of the ratio Bax/Bcl-2.
目的:观察西妥昔单抗诱导人鼻咽癌细胞株CNE凋亡的效果,并初步探讨其可能机制。方法:MTT法测定西妥昔单抗对CNE细胞株20～30%抑制的工作浓度;以该浓度药物作用CNE细胞,透射电镜、Hochest33258荧光染色法观察其凋亡形态学变化,流式细胞术检测凋亡率;western blot检测Bax、Bcl-2蛋白的表达。结果:西妥昔单抗对CNE细胞株的工作浓度(IC20～30)为10ug/ml;CNE细胞经西妥昔单抗处理后,电镜、荧光显微镜下均可见典型的凋亡形态学及超微结构改变;流式细胞术显示24、48h凋亡率分别为14.30±0.78%、15.30±0.95%,显著高于对照组(P<0.05);western blot检测显示Bax蛋白表达上调、Bcl-2蛋白表达下调、Bax/Bcl-2比值增加。结论:西妥昔单抗对人鼻咽癌细胞株CNE有显著的凋亡诱导作用,这可能与其上调Bax/Bcl-2比值促进凋亡有关。
第二部分:西妥昔单抗联合热疗诱导人鼻咽癌细胞株CNE凋亡实验研究
目的:观察西妥昔单抗联合热疗诱导人鼻咽癌细胞株CNE凋亡的效果,并初步探讨其可能的机制。方法:试验分单靶组、单热组及热靶组,Hochest33258荧光染色法观察CNE细胞株各处理组细胞凋亡形态学变化;流式细胞术检测凋亡率;western blot检测CNE细胞株不同处理后Bax、Bcl-2、EGFR以及热疗后不同时间EGFR蛋白的表达。结果:荧光染色法观察到CNE细胞发生典型的凋亡形态学改变,以热靶组更为显著;流式凋亡检测显示热靶组凋亡率显著高于单靶组、单热组及对照组(P<0.05);western blot检测显示各处理组较之对照组都有上调Bax/Bcl-2比值、下调EGFR蛋白表达作用,以热靶组最为显著(P<0.05);热疗后随时间的延长,EGFR蛋白表达逐渐下调。结论:西妥昔单抗联合低温热疗能显著增加CNE细胞的凋亡率,这可能与EGFR的下调与受抑,进而调变Bax/Bcl-2比值进一步促进凋亡有关。
第三部分:西妥昔单抗联合放疗及热疗诱导人鼻咽癌细胞株CNE凋亡实验研究
目的:观察西妥昔单抗联合放疗及低温热疗体外诱导人鼻咽癌细胞株CNE凋亡的效果,并初步探讨其可能的机制。方法:试验分对照组、单放组、热放组、靶放组及热靶放组,Hochest 33258荧光染色法观察CNE细胞株细胞凋亡形态学变化;流式细胞术检测凋亡率; Western blot检测各组Bax、Bcl-2蛋白的表达。结果:荧光染色法观察到CNE细胞发生典型的凋亡形态学改变,以靶放热组更为显著;流式凋亡检测显示各照射剂量下靶放热组凋亡率显著高于对照组及相应单放组、热放组、靶放组(P<0.05);western blot检测显示各处理组较之对照组都有上调Bax/Bcl-2比值,以靶放热组最为显著(P<0.05)。结论:西妥昔单抗联合放疗和低温热疗显著增加CNE细胞的凋亡率,这可能与其上调Bax/Bcl-2比值进一步促进凋亡有关。
Part One: The experimental study on apoptosis of human nasopharyngeal carcinoma CNE cell line induced by cetuximab in vitro Objective: To investigate the apoptosis mechanism of CNE cell line induced by cetuximab in vitro. Methods: The working concentration of cetuximab was defined as its IC(20～30) at 48 hours action against CNE which was determined by MTT assay. Cells apoptosis was assayed by transmission electron microscopy(TEM), fluorescent Hocehst 33258 staining and flow cytometric analysis(FCM). The expression of Bcl- 2、Bax proteins were determined by Western Blot. Results: A working concentration of Cetuximab at 10μg/ml was obtained and subsequently used in the following experiments. Characteristical changes of apoptosis in CNE cells were observed and the apoptosis rate of 24, 48h was 14.30±0.78%, 15.30±0.95% respectively(P<0.05 compared with control group). In addition, Western Blot analysis indicated the level of expression of the proteins Bax significantly increased while Bcl-2 decreased by the treatment. Conclusion: Cetuximab could significantly induce the apoptosis of CNE cells, possibly through the Bax up-regulation and Bcl-2 down-regulation.
Part Two : The experimental study on apoptosis of human nasopharyngeal carcinoma CNE cell line induced by cetuximab combined with hyperthermia in vitro
Objective: To investigate the apoptosis mechanism of CNE cell line induced by cetuximab combined with hyperthermia in vitro. Methods: Apoptosis was assayed by fluorescent Hochest 33258 staining and flow cytometry(FCM) in three experimental groups: cetuximab(10ug/ml) or hyperthermia(43℃, 30min) alone, cetuximab combined with hyperthermia. The expression of Bax, Bcl-2, EGFR proteins were determined by Western Blot. Results: Characteristical changes of apoptosis in CNE cells were observed in all experimental groups, especially in cetuximab combined with hyperthermia group. FCM also showed more prominent apoptosis induced by cetuximab combined with hyperthermia group compared to cetuximab or hyperthermia alone groups. Western Blot analysis indicated that the ratio of Bax/Bcl-2 significantly increased while the expression of the protein EGFR decreased by the treatment,the level of expression of the protein EGFR decreased gradually after the treatment of hyperthermia. Conclusion: Cetuximab combined with hyperthermia synergistically increases the apoptosis in CNE cells, possibly by further down-regulating expression of EGFR to up-regulate Bax/Bcl-2 ratio.
Part Three : The experimental study on apoptosis of human nasopharyngeal carcinoma CNE cell line induced by cetuximab in conjunction with radiotherapy and hyperthermia in vitro
Objective: To investigate the apoptosis mechanism of CNE cell line induced by Cetuximab in conjunction with radiotherapy and hyperthermia in vitro. Methods:Apoptosis was assayed by fluorescent Hocehst 33258 staining and flow cytometry (FCM) in five experimental groups: control with no treatment (C), radiotherapy alone(2、4、8、12Gy)(R), Cetuximab with radiotherapy(TR), Cetuximab with hyperthermia(43℃, 30min)(TH), and Cetuximab with radiotherapy plus hyperthermia(TRH). The expression of Bcl-2, Bax proteins were determined by Western Blot. Results: Characteristical changes of apoptosis in cells treated with cetuximab were observed in all the experimental groups, especially in TRH. FCM also showed more prominent apoptosis induced by TRH group compared to the control, R, TR and RH groups. In addition, Western Blot analysis indicated that the ratio of the proteins Bax/Bcl-2 by the treatment. Conclusion: Cetuximab in conjunction with radiotherapy and hyperthermia synergistically increases the apoptosis in CNE cells, possibly through further up-regulation of the ratio Bax/Bcl-2.
引文
[1]Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008 Jun 15;112(12):2635-45. PMID: 18442098
[2]Zureikat AH, McKee MD. Targeted therapy for solid tumors: current status. Surg Oncol Clin N Am. 2008 Apr;17(2):279-301. PMID:18375353
[3]Ma BB, Poon TC, To KF, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. Head Neck. 2003 Oct;25(10):864-72. PMID: 12966511
[4]Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):11-20. PMID: 15093894
[5]Mosmann T.Rapid colorimetic assay for celluar growth and survival:Application to proliferation and cytotoxicity assay.J Immunol Methods,1983;65:55
[6]杨怡,张德添,张飒,等.培养细胞透射电镜超薄切片制备方法.电子显微学报, 2004年04期:228
[7]陶忠芬,可金星,肖桃元,等.电镜样品取材的意义与应用.第三军医大学学报, 2005年03期:93-94
[8]王娜,侯琳,祝兆怡,等. 2,3-吲哚醌对人神经母细胞瘤细胞SH-SY5Y凋亡和端粒酶表达的影响.中国药理学通报. 2007May; 23 (5) : 680-4
[9]Vermes I, Haanen C, Steffens-Nakken H et al. A novel assay for apoptosis.Flow cytometric detection of phosphatidylserine expression on earlyapoptosis cells using fluorescein labeled Annexin V. J Immunol Methods,1995; 184:39
[10]Decai Yu, Linyuan Zhuang, Xitai Sun, et al. Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma. BMC Cancer. 2007 Jul 4;7:122. PMID: 17608955
[11]Burgess AW. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors. 2008 Oct;26(5):263-74. Review. PMID: 18800267
[12]Huether A, H?pfner M, Baradari V, et al. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol. 2005 Nov 25;70(11):1568-78. PMID: 16226226
[13]Rivera F, Vega-Villegas ME, López-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs. 2008 Feb;19(2):99-113. Review. PMID: 18176106
[14]Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol. 2007 Oct;19(5):488-96. PMID: 17629468
[1]尚学兰,谢志强,黄志碧.鼻咽癌的危险因素.现代预防医学, 2008, 35(2):206-207.
[2]赵充,管迅行.鼻咽癌放化综合治疗临床研究现状.中华肿瘤防治杂志, 2006, 13(6): 0001-0004.
[3]Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets, 2007 Nov;7(7):650-665. PMID: 18045070
[4]Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol, 2005 May 20, 23(15):3568-3576. PMID: 15809453
[5]Melet A, Song K, Bucur O, et al. Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol, 2008, 615:47-79. PMID: 18437891
[6]Ren H, Yang BF, Rainov NG. Receptor tyrosine kinases as therapeutic targets in malignant glioma. Rev Recent Clin Trials, 2007 May, 2(2):87- 101. PMID: 18473993
[7]Metro G, Finocchiaro G, Toschi L, et al. Epidermal growth factor receptor(EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials, 2006 Jan, 1(1):1-13. PMID: 18393776
[8]Moyer HR, Delman KA. The role of hyperthermia in optimizing tumor response to regional therapy. Int J Hyperthermia, 2008 May, 24(3):251-261. PMID: 18393003
[9]Hildebrandt B, Wust P. The biologic rationale of hyperthermia. Cancer Treat Res, 2007, 134:171-184. PMID: 17633053
[10]彭远飞,郑民华.肿瘤热疗的细胞分子作用机制及应用进展.世界华人消化杂志, 2007, 15(12): 1319-1323.
[11]Burd R, Dziedzic TS, Xu Y, et al. Tumor cell apoptosis , lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J Cell Physiol, 1998, 177 (1) :137-147. PMID: 9731754
[12]Tang R, Zhu ZG, Qu Y, et al. The impact of hyperthermic chemotherapy on human gastric cancer cell lines: preliminary results. Oncol Rep. 2006 Sep;16(3):631-41. PMID: 16865266
[13]毛荣军,谭宇敏. EGFR及p16蛋白在鼻咽癌中的异常表达.实用癌症杂志, 1999, 14(3):182-184.
[14]Dutta PR, Maity A .Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett, 2007 Sep 8, 254(2):165-77. PMID: 17367921.
[15]Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol, 2007 Oct, 19(5):488-96. PMID: 17629468.
[1]尚学兰,谢志强,黄志碧.鼻咽癌的危险因素.现代预防医学, 2008, 35(2):206-207.
[2]赵充,管迅行.鼻咽癌放化综合治疗临床研究现状.中华肿瘤防治杂志, 2006, 13(6): 0001-0004.
[3]LinksMetro G, Finocchiaro G, Toschi L, et al. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). RevRecent Clin Trials. 2006 Jan;1(1):1-13. PMID: 18393776
[4]Fiorentini G, Szasz A. Hyperthermia today: electric energy, a new opportunity in cancer treatment. J Cancer Res Ther. 2006 Apr-Jun;2(2):41-6.PMID: 17998673
[5]Hwang JM, Fu KK, Phillips TL. Results and prognostic factors in the retreatment of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1099-111. PMID: 9719121
[6]Huang XD, Yi JL, Gao L, et al.[Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma] Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):197-201. Chinese. PMID: 17649636
[7]Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008 Apr 28. PMID: 18442098
[8]毛荣军,谭宇敏. EGFR及p16蛋白在鼻咽癌中的异常表达.实用癌症杂志, 1999, 14(3):182-184.
[9]Dutta PR, Maity A .Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 2007 Sep 8;254(2):165-77. PMID: 17367921
[10]Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007 Jun 1;25(16):2191-7. PMID: 17538164
[11]Feng FY, Lopez CA, Normolle DP et al. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res. 2007 Apr 15;13(8):2512-8. PMID: 17438112
[12]Fuwa N, Shikama N, Hayashi N, et al. Treatment results of alternatingchemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil--a phase II study. Oral Oncol. 2007 Oct;43(9):948-55. PMID: 17257880
[13]Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40. PMID: 10213503
[14]Burd R、Dziedzic TS、Xu Y,et al .Tumor cell apoptosis , lymphocyte recruitment and tumor vascular changes are induced by low temperature , long duration (fever-like) whole body hyperthermia. J Cell Physiol ,1998 ,177 (1) :1372147. PMID: 9731754
[15]Raaphorst GP, Feeley MM, Danjoux CE, et al. Hyperthermia enhancement of radiation response and inhibition of recovery from radiation damage in human glioma cells. Int J Hyperthermia. 1991 Jul-Aug;7(4):629-41. PMID: 1919158
[16]Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol. 2007 Oct;19(5):488-96. PMID: 17629468
[1]于金明,徐忠法.肿瘤临床通鉴.济南山东科学技术出版社, 2004:296.
[2]Kam MK, Chau RM, Suen J, et al. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: Dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys, 2003, 56:145-157.
[3]Wu VW, Kwong DL, Sham JS. Target dose conformity in 3-dimensional conformal radiotherapy and intensity modulated radiotherapy. Radiother Oncol, 2004,71: 201-206.
[4]Paulino AC, Koshy M, Howell R, et al. Comparison of CT and FDG-PET-defined gross tumor volume in intensitymodulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys, 2005,61:1385-1392.
[5]卢丽霞,赵充,韩非,等.鼻咽癌照射靶体积划定的临床探讨仁.中华放射肿瘤学杂志,2005,14(2):81-84.
[6]Lee N, Garden A, Kramer A, et al. Aphase11studyofintensity modulated radiationtherapy(IMRT)+/-Chemotherapy for nasopharyngeal Cancer.rtog 0225 protocal.
[7]Gilbeau L, Octave-Prignot M, Loncol T, et al. Comparison of setup accuracy of three different thermoplastic masks for the treatment of brain and head and neck tumors. Radiother Oncol. 2001,58:155-162.
[8]Sultanem K, Shu HK, Xia P, et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys, 2000, 48: 711-722.
[9]Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys, 2002, 53: 12-22.
[10]Chan AT, Teo PM, Leung TW, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 1995, 33(3):569-577.
[11]Hareyama M, Sakata KI, Shirato, et al. A prospective randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer, 2002, 94(8):2217-2223.
[12]EI-Weshi A, Khafaga Y, Allam A, et al. Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfraction in stageⅢandⅣnasopharyngeal carcinoma-a phaseⅡstudy[J]. Acta Oncol, 2001, 40(5):574-581.
[13]Ma J, Mai HQ, Hong MH, et al. Results of prospective randomized trial comparing neoneoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. JClin Oncol, 2001, 19(5):1350-1356.
[14]崔念基,卢泰祥,邓小武,等.第二届全国鼻咽癌放射治疗学术会议纪要.中华放射肿瘤学杂志. 2003, 12(1):71
[15]Lin JC, Jan JS, Hsu CY, et al. PhaseⅢstudy of cocurrent chemotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma:positive effect on overall and progression-free survival. J Clin Oncol, 2003, 21(4):631-637.
[16]文浩,郎锦义,扬家林,等.超分割放射同期化疗治疗Ⅲ和Ⅳ期鼻咽癌前瞻性研究.中华放射肿瘤学杂志, 2002, 11(2):73-76.
[17]Chi KH, Chang YC, Guo WY, et al. A phaseⅢstudy of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int Radiat Oncol Biol Phys, 2002, 52(5):1238-1244.
[18]Prasad U, Wahid MI, Jalaludin MA, et al. Long-term survival of nasopharyngeal carcinoma patients treated with adjuvant chemotherapy subsequent to conventional radical radiotherapy[J]. Int Radiat Oncol Biol Phys, 2002,53(3):648-655.
[19]罗彪,梁谨,黄世庆,等.中晚期鼻咽癌根治放疗后辅助化疗的疗效观察.肿瘤, 2005,25(4):408.
[20]Al-Amoro A, Al-Rajhi N, Khafaga Y, et al. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 2005, 62(2):508- 513.
[21]Ricardo Hitt, Antonio López-Pousa, Javier Martínez-Trufero,et al. PhaseⅢstudy comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol, 2005, 23(34):8636-8645.
[22]Chan AT, Ma BB, Lo YM, et al. PhaseⅡstudy of neoadjuvant carboplatinand paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol, 2004, 22(15):3053-3060.
[23]AI-Sarraf M, Le Blanc M, Gin P GS, et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer-phaseⅢrandomized intergroup study 0099. J Clin Oncol, 1998, 16(4):1310-1317.
[24]Lee AW, Tung S, Chua D, et al. Prospective randomized study on therapeutic gain achieved by addition of chemotherapy for T1~4N2~3M0 nasopharyngeal carcinoma(NPC). Proc Am Soc Clin Oncol, 2004, 23:487.
[25]黄晓东,易均林,高黎,等.抗表皮生长因子受体单克隆抗体h-R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究.中华肿瘤杂志, 2007,29(3):197-202.
[26]Chan ATC, Hsu MM, Goh BC, et al. Multicenter, PhaseⅡstudy of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol, 2005, 23(15): 3568- 3576.
[27]罗荣城,康世均.鼻咽癌生物治疗的实验和临床研究进展.肿瘤学杂志, 2008, 14(1):16-23.
[28]黄慧强,李宇红,何友兼. DDP、5Fu/CF加干扰素治疗晚期鼻咽癌的初步报告.癌症, 1998, 17(6):450- 452.
[29]董伟达,周蓉珏.新型重组人肿瘤坏死因子抗荷鼻咽癌裸鼠的实验研究.中华耳鼻咽喉科杂志, 1998, 33(1):38-41.
[30]李官成,谢鹭,周国华,等.用抗独特型疫苗主动免疫治疗鼻咽癌病人的临床研究.中华医学杂志(英文版), 2002, 115(4):567- 570.
[31]岳惠芬,刘名光,梁新强,等.新城疫病毒Ⅳ系活疫苗辅助治疗鼻咽癌患者的临床效果观察研究.中华肿瘤防治杂志, 2006, 13(16):1219- 1221.
[32]李华斌,谢民强,许庚,等.转导bax基因治疗实验性鼻咽癌的研究.中华耳鼻咽喉科杂志, 2001,36(6):430- 432.
[33]夏忠军,常建华,张力,等.基因工程腺病毒(H101)瘤内注射联合化疗治疗头颈部及食管鳞癌的Ⅲ期临床研究[J].癌症, 2004, 23(12): 1666- 1670.
[34]陈传本,潘建基,徐鹭英,等.重组人p53腺病毒注射液结合放射治疗鼻咽癌Ⅱ期临床试验观察[J].中华医学杂志, 2003, 83(24):2033- 2035.
[35]徐伯平,胡丕丽.中药散结方对鼻咽癌放疗增敏的研究.中医研究, 2001, 14(30):17-19.
[36]秦俭,滕家安,王仁生,等.肿节风浸膏对腮腺早期放射损伤作用的实验研究.中国辐射卫生. 2008, 17(3):269-271.
[1]Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol, 2003, 15(6):419-424.
[2]Grammatikakis N, Vultur A, Ramana CV, et al. The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem, 2002, 277(10):8312-8320.
[3]Kuo CC, Liang CM, Lai CY, et al. Involvement of heat shock protein (Hsp)90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide. J Immunol, 2007, 178(10):6100-6108.
[4]Queitsch C, Sangster TA, Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature, 2002, 417(6889):618-624.
[5]Rahmani M, Reese E, Dai Y, et al. Cotreatment with suberanoylanilidehydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol, 2005, 67(4):1166-1176.
[6]Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat Res, 2005, 569(1-2):75-85.
[7]Zanini C, Giribaldi G, Mandili G, et al. Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing's sarcoma cell lines. J Neurochem, 2007, 103(4):1344-1354.
[8]Workman P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med, 2004 , 10(2):47-51.
[9]Rohde M, Daugaard M, Jensen MH, et al. Members of the heat-shock protein70 family promote cancer cell growth by distinct mechanisms. Genes Dev, 2005 , 19(5):570-582.
[10]Wadhwa R, Taira K, Kaul SC. An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where? Cell Stress Chaperones, 2002 , 7(3):309-316.
[11]Saribek B, Jin Y, Saigo M, et al. HSP90beta is involved in signaling prolactin-induced apoptosis in newt testis. Biochem Biophys Res Commun, 2006 , 349(4):1190-1197.
[12]Nylandsted J, Gyrd-Hansen M, Danielewicz A, et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med, 2004 , 200(4):425-435.
[13]Nelson DA, White E. Exploiting different ways to die. Genes Dev, 2004, 18(11):1223-1226.
[14]Zhou J, Schmid T, Frank R, et al. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem, 2004 , 279(14):13506-13513.
[15]Sun J, Liao JK. Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol, 2004 , 24(12):2238-2244.
[16]Pfosser A, Thalgott M, Buttner K, et al. Liposomal Hsp90 cDNA induces neovascularization via nitric oxide in chronic ischemia. Cardiovasc Res, 2005, 65(3):728-736.
[17]Martinez JA, Tavarez JJ, Oliveira CM, et al. Potentiation of angiogenic switch in capillary endothelial cells by cAMP: A cross-talk between up-regulated LLO biosynthesis and the HSP-70 expression. Glycoconj J, 2006, 23(3-4):209-220.
[18]Kalogeraki A, Garbagnati F, Darivianaki K, et al. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes. Anticancer Res, 2006, 26(5A):3551-3554.
[19]Tsutsumi S, Neckers L. Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci, 2007, 98(10):1536-1539.
[20]Price JT, Quinn JM, Sims NA,et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res, 2005 , 65(11):4929-4938.
[21]Calderwood SK, Khaleque MA, Sawyer DB, et al. Heat shock proteins incancer: chaperones of tumorigenesis. Trends Biochem Sci, 2006, 31(3):164-172.
[22]Viatour P, Merville MP, Bours V, et al. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci, 2005, 30(1):43-52.
[23]Daniels GA, Sanchez-Perez L, Diaz RM, et al. A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol, 2004 , 22(9):1125-1132.
[24]Baronzio G, Gramaglia A, Fiorentini G. Hyperthermia and immunity. A brief overview. In Vivo, 2006 , 20(6A):689-695.
[25]Takakura Y, Takemoto S, Nishikawa M. Hsp-based tumor vaccines: State-of-the-art and future directions. Curr Opin Mol Ther, 2007, 9(4):385-391.
[2]Zureikat AH, McKee MD. Targeted therapy for solid tumors: current status. Surg Oncol Clin N Am. 2008 Apr;17(2):279-301. PMID:18375353
[3]Ma BB, Poon TC, To KF, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. Head Neck. 2003 Oct;25(10):864-72. PMID: 12966511
[4]Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):11-20. PMID: 15093894
[5]Mosmann T.Rapid colorimetic assay for celluar growth and survival:Application to proliferation and cytotoxicity assay.J Immunol Methods,1983;65:55
[6]杨怡,张德添,张飒,等.培养细胞透射电镜超薄切片制备方法.电子显微学报, 2004年04期:228
[7]陶忠芬,可金星,肖桃元,等.电镜样品取材的意义与应用.第三军医大学学报, 2005年03期:93-94
[8]王娜,侯琳,祝兆怡,等. 2,3-吲哚醌对人神经母细胞瘤细胞SH-SY5Y凋亡和端粒酶表达的影响.中国药理学通报. 2007May; 23 (5) : 680-4
[9]Vermes I, Haanen C, Steffens-Nakken H et al. A novel assay for apoptosis.Flow cytometric detection of phosphatidylserine expression on earlyapoptosis cells using fluorescein labeled Annexin V. J Immunol Methods,1995; 184:39
[10]Decai Yu, Linyuan Zhuang, Xitai Sun, et al. Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma. BMC Cancer. 2007 Jul 4;7:122. PMID: 17608955
[11]Burgess AW. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors. 2008 Oct;26(5):263-74. Review. PMID: 18800267
[12]Huether A, H?pfner M, Baradari V, et al. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol. 2005 Nov 25;70(11):1568-78. PMID: 16226226
[13]Rivera F, Vega-Villegas ME, López-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs. 2008 Feb;19(2):99-113. Review. PMID: 18176106
[14]Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol. 2007 Oct;19(5):488-96. PMID: 17629468
[1]尚学兰,谢志强,黄志碧.鼻咽癌的危险因素.现代预防医学, 2008, 35(2):206-207.
[2]赵充,管迅行.鼻咽癌放化综合治疗临床研究现状.中华肿瘤防治杂志, 2006, 13(6): 0001-0004.
[3]Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets, 2007 Nov;7(7):650-665. PMID: 18045070
[4]Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol, 2005 May 20, 23(15):3568-3576. PMID: 15809453
[5]Melet A, Song K, Bucur O, et al. Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol, 2008, 615:47-79. PMID: 18437891
[6]Ren H, Yang BF, Rainov NG. Receptor tyrosine kinases as therapeutic targets in malignant glioma. Rev Recent Clin Trials, 2007 May, 2(2):87- 101. PMID: 18473993
[7]Metro G, Finocchiaro G, Toschi L, et al. Epidermal growth factor receptor(EGFR) targeted therapies in non-small cell lung cancer (NSCLC). Rev Recent Clin Trials, 2006 Jan, 1(1):1-13. PMID: 18393776
[8]Moyer HR, Delman KA. The role of hyperthermia in optimizing tumor response to regional therapy. Int J Hyperthermia, 2008 May, 24(3):251-261. PMID: 18393003
[9]Hildebrandt B, Wust P. The biologic rationale of hyperthermia. Cancer Treat Res, 2007, 134:171-184. PMID: 17633053
[10]彭远飞,郑民华.肿瘤热疗的细胞分子作用机制及应用进展.世界华人消化杂志, 2007, 15(12): 1319-1323.
[11]Burd R, Dziedzic TS, Xu Y, et al. Tumor cell apoptosis , lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J Cell Physiol, 1998, 177 (1) :137-147. PMID: 9731754
[12]Tang R, Zhu ZG, Qu Y, et al. The impact of hyperthermic chemotherapy on human gastric cancer cell lines: preliminary results. Oncol Rep. 2006 Sep;16(3):631-41. PMID: 16865266
[13]毛荣军,谭宇敏. EGFR及p16蛋白在鼻咽癌中的异常表达.实用癌症杂志, 1999, 14(3):182-184.
[14]Dutta PR, Maity A .Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett, 2007 Sep 8, 254(2):165-77. PMID: 17367921.
[15]Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol, 2007 Oct, 19(5):488-96. PMID: 17629468.
[1]尚学兰,谢志强,黄志碧.鼻咽癌的危险因素.现代预防医学, 2008, 35(2):206-207.
[2]赵充,管迅行.鼻咽癌放化综合治疗临床研究现状.中华肿瘤防治杂志, 2006, 13(6): 0001-0004.
[3]LinksMetro G, Finocchiaro G, Toschi L, et al. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). RevRecent Clin Trials. 2006 Jan;1(1):1-13. PMID: 18393776
[4]Fiorentini G, Szasz A. Hyperthermia today: electric energy, a new opportunity in cancer treatment. J Cancer Res Ther. 2006 Apr-Jun;2(2):41-6.PMID: 17998673
[5]Hwang JM, Fu KK, Phillips TL. Results and prognostic factors in the retreatment of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1099-111. PMID: 9719121
[6]Huang XD, Yi JL, Gao L, et al.[Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma] Zhonghua Zhong Liu Za Zhi. 2007 Mar;29(3):197-201. Chinese. PMID: 17649636
[7]Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008 Apr 28. PMID: 18442098
[8]毛荣军,谭宇敏. EGFR及p16蛋白在鼻咽癌中的异常表达.实用癌症杂志, 1999, 14(3):182-184.
[9]Dutta PR, Maity A .Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 2007 Sep 8;254(2):165-77. PMID: 17367921
[10]Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007 Jun 1;25(16):2191-7. PMID: 17538164
[11]Feng FY, Lopez CA, Normolle DP et al. Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. Clin Cancer Res. 2007 Apr 15;13(8):2512-8. PMID: 17438112
[12]Fuwa N, Shikama N, Hayashi N, et al. Treatment results of alternatingchemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil--a phase II study. Oral Oncol. 2007 Oct;43(9):948-55. PMID: 17257880
[13]Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40. PMID: 10213503
[14]Burd R、Dziedzic TS、Xu Y,et al .Tumor cell apoptosis , lymphocyte recruitment and tumor vascular changes are induced by low temperature , long duration (fever-like) whole body hyperthermia. J Cell Physiol ,1998 ,177 (1) :1372147. PMID: 9731754
[15]Raaphorst GP, Feeley MM, Danjoux CE, et al. Hyperthermia enhancement of radiation response and inhibition of recovery from radiation damage in human glioma cells. Int J Hyperthermia. 1991 Jul-Aug;7(4):629-41. PMID: 1919158
[16]Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol. 2007 Oct;19(5):488-96. PMID: 17629468
[1]于金明,徐忠法.肿瘤临床通鉴.济南山东科学技术出版社, 2004:296.
[2]Kam MK, Chau RM, Suen J, et al. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: Dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys, 2003, 56:145-157.
[3]Wu VW, Kwong DL, Sham JS. Target dose conformity in 3-dimensional conformal radiotherapy and intensity modulated radiotherapy. Radiother Oncol, 2004,71: 201-206.
[4]Paulino AC, Koshy M, Howell R, et al. Comparison of CT and FDG-PET-defined gross tumor volume in intensitymodulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys, 2005,61:1385-1392.
[5]卢丽霞,赵充,韩非,等.鼻咽癌照射靶体积划定的临床探讨仁.中华放射肿瘤学杂志,2005,14(2):81-84.
[6]Lee N, Garden A, Kramer A, et al. Aphase11studyofintensity modulated radiationtherapy(IMRT)+/-Chemotherapy for nasopharyngeal Cancer.rtog 0225 protocal.
[7]Gilbeau L, Octave-Prignot M, Loncol T, et al. Comparison of setup accuracy of three different thermoplastic masks for the treatment of brain and head and neck tumors. Radiother Oncol. 2001,58:155-162.
[8]Sultanem K, Shu HK, Xia P, et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys, 2000, 48: 711-722.
[9]Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys, 2002, 53: 12-22.
[10]Chan AT, Teo PM, Leung TW, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 1995, 33(3):569-577.
[11]Hareyama M, Sakata KI, Shirato, et al. A prospective randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer, 2002, 94(8):2217-2223.
[12]EI-Weshi A, Khafaga Y, Allam A, et al. Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfraction in stageⅢandⅣnasopharyngeal carcinoma-a phaseⅡstudy[J]. Acta Oncol, 2001, 40(5):574-581.
[13]Ma J, Mai HQ, Hong MH, et al. Results of prospective randomized trial comparing neoneoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. JClin Oncol, 2001, 19(5):1350-1356.
[14]崔念基,卢泰祥,邓小武,等.第二届全国鼻咽癌放射治疗学术会议纪要.中华放射肿瘤学杂志. 2003, 12(1):71
[15]Lin JC, Jan JS, Hsu CY, et al. PhaseⅢstudy of cocurrent chemotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma:positive effect on overall and progression-free survival. J Clin Oncol, 2003, 21(4):631-637.
[16]文浩,郎锦义,扬家林,等.超分割放射同期化疗治疗Ⅲ和Ⅳ期鼻咽癌前瞻性研究.中华放射肿瘤学杂志, 2002, 11(2):73-76.
[17]Chi KH, Chang YC, Guo WY, et al. A phaseⅢstudy of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int Radiat Oncol Biol Phys, 2002, 52(5):1238-1244.
[18]Prasad U, Wahid MI, Jalaludin MA, et al. Long-term survival of nasopharyngeal carcinoma patients treated with adjuvant chemotherapy subsequent to conventional radical radiotherapy[J]. Int Radiat Oncol Biol Phys, 2002,53(3):648-655.
[19]罗彪,梁谨,黄世庆,等.中晚期鼻咽癌根治放疗后辅助化疗的疗效观察.肿瘤, 2005,25(4):408.
[20]Al-Amoro A, Al-Rajhi N, Khafaga Y, et al. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 2005, 62(2):508- 513.
[21]Ricardo Hitt, Antonio López-Pousa, Javier Martínez-Trufero,et al. PhaseⅢstudy comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol, 2005, 23(34):8636-8645.
[22]Chan AT, Ma BB, Lo YM, et al. PhaseⅡstudy of neoadjuvant carboplatinand paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol, 2004, 22(15):3053-3060.
[23]AI-Sarraf M, Le Blanc M, Gin P GS, et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer-phaseⅢrandomized intergroup study 0099. J Clin Oncol, 1998, 16(4):1310-1317.
[24]Lee AW, Tung S, Chua D, et al. Prospective randomized study on therapeutic gain achieved by addition of chemotherapy for T1~4N2~3M0 nasopharyngeal carcinoma(NPC). Proc Am Soc Clin Oncol, 2004, 23:487.
[25]黄晓东,易均林,高黎,等.抗表皮生长因子受体单克隆抗体h-R3联合放疗治疗晚期鼻咽癌的Ⅱ期临床研究.中华肿瘤杂志, 2007,29(3):197-202.
[26]Chan ATC, Hsu MM, Goh BC, et al. Multicenter, PhaseⅡstudy of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol, 2005, 23(15): 3568- 3576.
[27]罗荣城,康世均.鼻咽癌生物治疗的实验和临床研究进展.肿瘤学杂志, 2008, 14(1):16-23.
[28]黄慧强,李宇红,何友兼. DDP、5Fu/CF加干扰素治疗晚期鼻咽癌的初步报告.癌症, 1998, 17(6):450- 452.
[29]董伟达,周蓉珏.新型重组人肿瘤坏死因子抗荷鼻咽癌裸鼠的实验研究.中华耳鼻咽喉科杂志, 1998, 33(1):38-41.
[30]李官成,谢鹭,周国华,等.用抗独特型疫苗主动免疫治疗鼻咽癌病人的临床研究.中华医学杂志(英文版), 2002, 115(4):567- 570.
[31]岳惠芬,刘名光,梁新强,等.新城疫病毒Ⅳ系活疫苗辅助治疗鼻咽癌患者的临床效果观察研究.中华肿瘤防治杂志, 2006, 13(16):1219- 1221.
[32]李华斌,谢民强,许庚,等.转导bax基因治疗实验性鼻咽癌的研究.中华耳鼻咽喉科杂志, 2001,36(6):430- 432.
[33]夏忠军,常建华,张力,等.基因工程腺病毒(H101)瘤内注射联合化疗治疗头颈部及食管鳞癌的Ⅲ期临床研究[J].癌症, 2004, 23(12): 1666- 1670.
[34]陈传本,潘建基,徐鹭英,等.重组人p53腺病毒注射液结合放射治疗鼻咽癌Ⅱ期临床试验观察[J].中华医学杂志, 2003, 83(24):2033- 2035.
[35]徐伯平,胡丕丽.中药散结方对鼻咽癌放疗增敏的研究.中医研究, 2001, 14(30):17-19.
[36]秦俭,滕家安,王仁生,等.肿节风浸膏对腮腺早期放射损伤作用的实验研究.中国辐射卫生. 2008, 17(3):269-271.
[1]Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol, 2003, 15(6):419-424.
[2]Grammatikakis N, Vultur A, Ramana CV, et al. The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem, 2002, 277(10):8312-8320.
[3]Kuo CC, Liang CM, Lai CY, et al. Involvement of heat shock protein (Hsp)90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide. J Immunol, 2007, 178(10):6100-6108.
[4]Queitsch C, Sangster TA, Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature, 2002, 417(6889):618-624.
[5]Rahmani M, Reese E, Dai Y, et al. Cotreatment with suberanoylanilidehydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol Pharmacol, 2005, 67(4):1166-1176.
[6]Bindra RS, Glazer PM. Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat Res, 2005, 569(1-2):75-85.
[7]Zanini C, Giribaldi G, Mandili G, et al. Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing's sarcoma cell lines. J Neurochem, 2007, 103(4):1344-1354.
[8]Workman P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med, 2004 , 10(2):47-51.
[9]Rohde M, Daugaard M, Jensen MH, et al. Members of the heat-shock protein70 family promote cancer cell growth by distinct mechanisms. Genes Dev, 2005 , 19(5):570-582.
[10]Wadhwa R, Taira K, Kaul SC. An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where? Cell Stress Chaperones, 2002 , 7(3):309-316.
[11]Saribek B, Jin Y, Saigo M, et al. HSP90beta is involved in signaling prolactin-induced apoptosis in newt testis. Biochem Biophys Res Commun, 2006 , 349(4):1190-1197.
[12]Nylandsted J, Gyrd-Hansen M, Danielewicz A, et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med, 2004 , 200(4):425-435.
[13]Nelson DA, White E. Exploiting different ways to die. Genes Dev, 2004, 18(11):1223-1226.
[14]Zhou J, Schmid T, Frank R, et al. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J Biol Chem, 2004 , 279(14):13506-13513.
[15]Sun J, Liao JK. Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol, 2004 , 24(12):2238-2244.
[16]Pfosser A, Thalgott M, Buttner K, et al. Liposomal Hsp90 cDNA induces neovascularization via nitric oxide in chronic ischemia. Cardiovasc Res, 2005, 65(3):728-736.
[17]Martinez JA, Tavarez JJ, Oliveira CM, et al. Potentiation of angiogenic switch in capillary endothelial cells by cAMP: A cross-talk between up-regulated LLO biosynthesis and the HSP-70 expression. Glycoconj J, 2006, 23(3-4):209-220.
[18]Kalogeraki A, Garbagnati F, Darivianaki K, et al. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes. Anticancer Res, 2006, 26(5A):3551-3554.
[19]Tsutsumi S, Neckers L. Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis. Cancer Sci, 2007, 98(10):1536-1539.
[20]Price JT, Quinn JM, Sims NA,et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res, 2005 , 65(11):4929-4938.
[21]Calderwood SK, Khaleque MA, Sawyer DB, et al. Heat shock proteins incancer: chaperones of tumorigenesis. Trends Biochem Sci, 2006, 31(3):164-172.
[22]Viatour P, Merville MP, Bours V, et al. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci, 2005, 30(1):43-52.
[23]Daniels GA, Sanchez-Perez L, Diaz RM, et al. A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol, 2004 , 22(9):1125-1132.
[24]Baronzio G, Gramaglia A, Fiorentini G. Hyperthermia and immunity. A brief overview. In Vivo, 2006 , 20(6A):689-695.
[25]Takakura Y, Takemoto S, Nishikawa M. Hsp-based tumor vaccines: State-of-the-art and future directions. Curr Opin Mol Ther, 2007, 9(4):385-391.